Lupin launches Covid-19 drug Favipiravir In India at Rs 49 par tablet

    Drug major lupin on Wednesday announced the launch of its favipiravir durg under the brand name 'covihalt' for the treatment p...

 

  Drug major lupin on Wednesday announced the launch of its favipiravir durg under the brand name 'covihalt' for the treatment patients with mild to moderate COVID-19 symptoms at Rs 49 per tablet in India.                     Favipiravir has received authorisation from the Drug Controller General of India(DCGI) for emergency use, Lupin said in a regulatory filing.

  Coronavirus outbreak: updates. Its Covihalt dosage strength has been developed keeping in mind convenience of administration, it stated, adding that the drug is available as 200 mg tablets in the form of a strip of10 tablets, and priced at Rs 49 per tablet.

     Lupin president India Region Formulations (IRF) Rajeev sibal said the company believes that it can leve leverage its expertise in managing widespread community diseases like tuberculosis to

proactively reach patients across India and ensure access to Covihalt through its strong distribution network and field force.                       On August 4, sun parametrical Industries had launched Favipiravir under the brand name "FluGuard'' for the treatment of mild to moderate cases of Covid-19, at Rs 35 per tablet in India.